STOCK TITAN

T3 Defense (DFNS) 424B Filings

DFNS NASDAQ

Ticker history: NUKK became DFNS (T3 Defense Inc.) on . Earlier news and filings retain their original names and dates. View NUKK history.

Here are the 424B prospectus supplements from T3 Defense Inc. (DFNS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow DFNS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DFNS filings page.

Rhea-AI Summary

T3 Defense Inc. registered up to 7,051,799 common shares for resale by selling stockholders: up to 1,980,198 shares issuable on conversion of Series B preferred stock and 5,071,601 shares issuable on exercise of common warrants. T3 is not selling shares and receives no proceeds from resales; it may receive proceeds from cash exercises of warrants. The preferred shares and warrants have beneficial-ownership blockers of 9.9% and 9.99%, respectively. Shares outstanding were 3,250,296 as of September 30, 2026.

T3 describes a shift from financial technology to aerospace and defense, with a portfolio of defense and aerospace businesses. As of June 30, 2026, it reported approximately $131 million in negative working capital, including $124 million in stock purchase warrant liabilities that will not require cash to extinguish, and a $19 million stockholders’ deficit. For the six months ended June 30, 2026, net operating loss was $7.2 million and net cash used in operations was $9.8 million. Management said its plans, including approximately $4.1 million in unrestricted cash and an equity line of credit, alleviate substantial doubt about the company’s ability to continue as a going concern.

Rhea-AI Summary

T3 Defense Inc. (DFNS) registered up to 10,000,000 common shares for resale by Esousa Group Holdings, LLC. T3 may issue shares to Esousa under its committed equity purchase agreement, but receives no proceeds from Esousa’s resales. Separately, T3 may sell common stock to Esousa at its discretion, subject to the agreement’s conditions and the shares covered by this prospectus, for up to $250,000,000 in aggregate purchase price. The share block would represent approximately 75% of outstanding shares upon issuance, excluding applicable beneficial-ownership limitations; T3 had 3,250,296 shares outstanding as of September 30, 2026. The agreement bars T3 from directing a purchase that would take Esousa and its affiliates above 9.99% beneficial ownership.

For the six months ended June 30, 2026, T3 used $9.8 million of net cash in operations and said additional liquidity would be required for the next 12 months absent other action. Management concluded its plans alleviate substantial doubt about continued operations, including approximately $4.1 million of unrestricted cash and an active equity line with drawdown capacity exceeding projected annual operating cash needs.

Rhea-AI Summary

T3 Defense Inc. registers for resale up to 30,000,000 shares of its common stock by certain selling stockholders, consisting of up to 26,666,667 Conversion Shares issuable upon conversion of Series B Preferred Stock and up to 3,333,333 Warrant Shares issuable upon exercise of Common Warrants.

The prospectus states the company will not receive proceeds from secondary sales but would receive proceeds if the Common Warrants are exercised for cash; full exercise of those warrants for cash would generate approximately $15 million. The resale registration arises from the February 2026 Private Placement and is subject to conversion/exercise mechanics, blocker limits (9.9%/9.99%), anti-dilution adjustments, and stockholder approval conditions described in the prospectus.